FORM 8-K DATED 5/15/2003

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 


 

Form 8-K

 


 

 

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported)

 

May 15, 2003

 

 

CORTEX PHARMACEUTICALS, INC.


(Exact name of registrant as specified in its charter)

Delaware


  

0-17951


  

33-0303583


(State or other jurisdiction of

incorporation)

  

(Commission File Number)

  

(I.R.S Employer Identification No.)

 

 

15241 Barranca Parkway

Irvine, California


  

92618


(Address of principal executive offices)

  

(Zip Code)

 

 

 

Registrant’s telephone number, including area code: (949) 727-3157


N/A


(Former name or former address, if changed since last report.)

 

 



 

Item 7.    Financial Statements and Exhibits.

 

  (a)   Financial Statements of Businesses Acquired: None.

 

  (b)   Pro Forma Financial Information: None.

 

  (c)   Exhibits.

 

Exhibit

Number

  

Description

99.1

  

Press release of Cortex Pharmaceuticals, Inc. dated May 15, 2003.

 

 

Item 9.    Regulation FD Disclosure.

 

On May 15, 2003, Cortex Pharmaceuticals, Inc. issued a press release to report its financial results for the quarter ended March 31, 2003. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

All of the foregoing information is being furnished under Item 12 – Results of Operations and Financial Condition. It is being furnished under Item 9 of this Form 8-K in accordance with interim guidance issued by the SEC in Release No. 33-8216. Such information, including the Exhibits attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

       

CORTEX PHARMACEUTICALS, INC.

Date: May 15, 2003

     

By:

 

/s/    MARIA S. MESSINGER


               

Maria S. Messinger

Vice President, Chief Financial Officer

and Corporate Secretary

 

2


 

EXHIBIT INDEX

 

Exhibit

Number

  

Description

  

Sequential

Page No.


99.1

  

Press release of Cortex Pharmaceuticals, Inc. dated May 15, 2003.

  

4

 

3